Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia

PURPOSE: The present study aimed to compare treatment outcome of idarubicin versus doxorubicin in combination with Ara-C as induction therapy for untreated AML patients. PATIENTS AND METHODS: This retrospective study included 143 patients with de novo AML. All patients received full dose of standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherif, Hemat Afifi, Magdy, Ahmed, Elshesheni, Heba Anees, Ramadan, Sherein Mahmoud, Rashed, Reham A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517376/
https://www.ncbi.nlm.nih.gov/pubmed/34692402
http://dx.doi.org/10.1016/j.lrr.2021.100272
_version_ 1784584003410460672
author Sherif, Hemat Afifi
Magdy, Ahmed
Elshesheni, Heba Anees
Ramadan, Sherein Mahmoud
Rashed, Reham A.
author_facet Sherif, Hemat Afifi
Magdy, Ahmed
Elshesheni, Heba Anees
Ramadan, Sherein Mahmoud
Rashed, Reham A.
author_sort Sherif, Hemat Afifi
collection PubMed
description PURPOSE: The present study aimed to compare treatment outcome of idarubicin versus doxorubicin in combination with Ara-C as induction therapy for untreated AML patients. PATIENTS AND METHODS: This retrospective study included 143 patients with de novo AML. All patients received full dose of standard induction therapy (3 + 7) using anthracyclines (doxorubicin or idarubicin) and cytarabine. RESULTS: The studied groups had comparable CR. No significant differences were noted between the studied groups regarding DFS and OS. The DXR group had significantly lower cost in comparison to IDA group. CONCLUSIONS: Idarubicin doesn't have a clear advantage over doxorubicin in treatment of AML.
format Online
Article
Text
id pubmed-8517376
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-85173762021-10-21 Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia Sherif, Hemat Afifi Magdy, Ahmed Elshesheni, Heba Anees Ramadan, Sherein Mahmoud Rashed, Reham A. Leuk Res Rep Article PURPOSE: The present study aimed to compare treatment outcome of idarubicin versus doxorubicin in combination with Ara-C as induction therapy for untreated AML patients. PATIENTS AND METHODS: This retrospective study included 143 patients with de novo AML. All patients received full dose of standard induction therapy (3 + 7) using anthracyclines (doxorubicin or idarubicin) and cytarabine. RESULTS: The studied groups had comparable CR. No significant differences were noted between the studied groups regarding DFS and OS. The DXR group had significantly lower cost in comparison to IDA group. CONCLUSIONS: Idarubicin doesn't have a clear advantage over doxorubicin in treatment of AML. Elsevier 2021-10-07 /pmc/articles/PMC8517376/ /pubmed/34692402 http://dx.doi.org/10.1016/j.lrr.2021.100272 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Sherif, Hemat Afifi
Magdy, Ahmed
Elshesheni, Heba Anees
Ramadan, Sherein Mahmoud
Rashed, Reham A.
Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
title Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
title_full Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
title_fullStr Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
title_full_unstemmed Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
title_short Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
title_sort treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517376/
https://www.ncbi.nlm.nih.gov/pubmed/34692402
http://dx.doi.org/10.1016/j.lrr.2021.100272
work_keys_str_mv AT sherifhematafifi treatmentoutcomeofdoxorubicinversusidarubicininadultacutemyeloidleukemia
AT magdyahmed treatmentoutcomeofdoxorubicinversusidarubicininadultacutemyeloidleukemia
AT elsheshenihebaanees treatmentoutcomeofdoxorubicinversusidarubicininadultacutemyeloidleukemia
AT ramadanshereinmahmoud treatmentoutcomeofdoxorubicinversusidarubicininadultacutemyeloidleukemia
AT rashedrehama treatmentoutcomeofdoxorubicinversusidarubicininadultacutemyeloidleukemia

Ejemplares similares